Because readers are likely to encounter and assess individual publications, NHS EED abstracts reflect the original publication as it is written, as a stand-alone paper. Where NHS EED abstractors are able to identify positively that a publication is significantly linked to or informed by other publications, these will be referenced in the text of the abstract and their bibliographic details recorded here for information.
Wingard J R, Herbrecht R, Marciniak A, et al. Hospital resource utilization in acute invasive aspergillosis (AIA) patients (Pts) treated with voriconazole (VOR) or amphotericin B (CAB). Blood 2004;104. Abstract No.:88.
Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. New Engl J Med 2002;347:408-15.
Wenzel R, Del Favero A, Kibbler C, et al. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J Antimicrob Chemother 2005;55:352-61.
Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Ther 2001;132:301-2.
Kaiser L, Huguenin T, Lew PD, et al. Invasive aspergillosis. Clinical features of 35 proven cases at a single institution. Medicine 1998;77:188-94.